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Background: The status of ovarian reserve markers during hormonal contraception (HC) remains uncertain 
with conflicting literature data. The purpose of this study was to assess the impact of hormonal contraception 
(HC) on circulating anti-Müllerian hormone (AMH) and other ovarian reserve markers. Methods: A systematic 
review was conducted including all cohort, cross-sectional and randomized controlled studies assessing serum 
anti Müllerian hormone concentration in women using hormonal contraception. Data sources included 
MEDLINE, EMBASE, Dynamed Plus, ScienceDirect, TRIP database, ClinicalTrials.gov and the Cochrane 
Library from January 2000 to October 2018.  Results: A total of 366 studies were identified, of which 15 were 
eligible including 3280 women, mostly using combined hormonal contraception (CHC). Articles were divided 
according to duration of HC into short- (2-3 weeks), medium- (2-6 months), long- (>1year) and varied-term 
studies. Two study designs were identified including studies comparing AMH before and during/after CHC and 
studies comparing CHC users versus non-users. Short- and medium-term studies (n=284) reported no change in 
circulating AMH in women using cyclical CHC for 1-6 cycles. Apart from one study, all long- and varied-term 
studies (six studies, n=1601) consistently showed a marked decline in AMH, antral follicle count (AFC) and 
ovarian volume (OV). Three long-term studies (n=1324) provided evidence of AMH recovery after 
discontinuation of HC. Conclusion: circulating AMH seems to remain unchanged in women using cyclical 
CHC for up to six months, but appears to markedly decline in long-term users with recovery after 
discontinuation.  
Registration number: PROSPERO (CRD42016046703). 
 








Currently, an increasing number of women particularly in the developed world are on long-term hormonal 
contraception (HC) for various reasons such as education, career establishment, partnership changes and 
economic uncertainty.1 On the other hand, there has been a growing demand amongst young women, including 
those on long-term HC, to establish their fertility status and to assess their reproductive lifespan in order to help 
them plan their future.2,3 However, most long-term HC usurers would not want to risk a pregnancy by stopping 
their contraception for ovarian reserve assessment.  
Commonly used ovarian reserve tests include biochemical markers such as circulating follicle stimulating 
hormone (FSH), inhibin B, oestradiol (E2) and anti-Müllerian hormone (AMH) and ultrasound markers 
including antral follicle count (AFC) and ovarian volume (OV). Currently, circulating AMH is widely accepted 
as the most reliable biochemical ovarian reserve marker, which correlates well with the AFC.4   
Oral combined hormonal contraception (CHC) is widely used as a safe, effective and reversible method. Its 
contraceptive effect is mainly achieved by suppression of the hypothalamo-pituitary-ovarian (HPO) axis, with 
subsequent inhibition of folliculogenesis and ovulation.5 The 7-day hormone-free interval is usually associated 
with some recovery of the HPO axis, with resumption of follicle growth.6 It is possible that this recovery could 
maintain normal ovarian reserve as assessed by the number of small antral follicles and circulating anti-
Müllerian hormone (AMH). This hypothesis remains to be investigated. 
Although, literature data are consistent on the inhibitory effect of HC on FSH and E2, data on AMH during HC 
are conflicting. According to earlier studies it was generally believed that circulating AMH acts as an 
autocrine/paracrine, rather than a systemic factor, which is not influenced by the hypothalamo-pituitary ovarian 
(HPO) axis.7 This view was supported by several early studies confirming the stability of circulating AMH 
during different phases of the menstrual cycle.8-12 Based on this concept, it has been suggested that circulating 
AMH may not be affected by HC. More recent studies, however, revealed that AMH levels fluctuate 





A recent systematic review of endocrine and sonographic markers of ovarian function during HC highlighted 
the controversy over the status of AMH.15 However, the focus of that review was on ovarian morphological 
parameters with exclusion of the majority of studies assessing AMH. Whilst, some studies reported decline in 
circulating AMH in HC users,16-24 others found no change in AMH.25-29 
Based on the above, the status of circulating AMH as well as other ovarian reserve markers in HC users remains 
largely uncertain. We have therefore designed this systematic review to address this uncertainty. 
Methods 
This systematic review was designed in accordance with Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines30 and was prospectively registered in PROSPERO (CRD42016046703). 
We considered all published cohort (retrospective and prospective) and cross-sectional studies as well as 
randomized trials that investigated circulating AMH in women using HC. 
The primary outcome measure was serum AMH concentration and the secondary measures included AFC, OV, 
serum concentrations of FSH and E2 
Search strategy 
A search was conducted using various electronic databases from January 2000 to July 2017 (AMH was not in 
use before 2000). These databases included MEDLINE, EMBASE, Dynamed Plus, ScienceDirect, TRIP 
database, ClinicalTrials.gov and the Cochrane Library. Combinations of the following MeSH terms were used:  
hormonal contraception, oral contraception, combined contraception, contraceptive agents, intrauterine devices, 
Anti-Müllerian Hormone, Follicle Stimulating Hormone, ovarian follicle, ovarian reserve, and ovarian function 
tests. In addition to using MeSH terms search, title and abstract searches were also undertaken. Papers were 
limited to English Language, Human Studies and females. An accredited Clinical Librarian (CJ) performed the 
searches, which were then independently repeated by a second accredited Librarian using the same criteria. All 
identified articles were retrieved, and their reference lists were manually checked for further relevant studies. 






Title and abstract of all identified articles were screened independently by two reviewers (AM, CJ) to assess 
relevance to this systematic review. In case of disagreement, the full text was retrieved and reviewed 
independently by a senior author (SA) for a final decision. 
All identified articles were evaluated according to a standardized format including study design, methods, 
participant characteristics, intervention, and results. Two investigators (AM, SA) assessed eligibility of the 
studies independently. In case of discrepancies, a consensus was reached after discussion. 
Quality of included studies and risk of bias assessment  
Modified Newcastle-Ottawa tool was used to assess the quality and risk of bias of the included studies.31-33 Each 
article was scored according to three categories including selection (maximum three stars), comparability (four 
stars), and outcomes (two stars). Selection was rated according to recruitment bias, selection of consecutive 
participants and power calculation. Comparability was assessed based on adjustment of analysis for four 
confounders including patients’ age (<40), age-matching in cross-sectional and randomised studies, baseline 
serum AMH in cohort studies and the type and duration of hormonal contraception. Outcome was scored 
according to completeness of a follow-up period of at least three weeks for the short-term studies, three months 
for the medium-term studies and one year for the long-term studies. In the current analysis, we have given more 
weight to comparability factors and used the cut-off level of six stars with a minimum of three stars in the 
comparability category. Each article was scored initially by one author (AM) and then independantly reviewed 
and finalised by a second author (SA). All studies were included in the review with refernce to studies, which 
rate high on the quality assessment tool. Table 1 shows the results of quality scores of all studies in this review. 
Results 
Characteristics of included Studies   
A total of 366 studies were identified through the electronic search, of which 347 did not measure AMH and 





in full. Of these, two studies were excluded either due to lack of comparative AMH data34 or duplication.35 Tow 
further studies including women with PCOS were excluded.15,26 A total of 15 studies including 3280 HC users 
were eligible for the review, of which, 13 measured circulating AMH during HC.16,18-27,29,36 The remaining two 
articles assessed AMH after HC discontinuation.37,38 Details of the 17 included studies are shown in Tables 2 
and 3.  
Eight studies scored ≥ six on the modified Newcastle-Ottawa tool and were deemed of high quality.15,19,24-27,35 
The high heterogeneity between the included studies precluded a quantitate synthesis of the data.  Studies varied 
significantly in designs, statistical methods, HC types, duration of follow up and types of AMH assays. A 
narrative synthesis was therefore applied without meta-analysis.  
Study designs 
This review included four cohort studies,16,25,27,38 three RCTs,19, 24, 34 and eight cross-sectional studies.8-20,22-24,29,37 
In all RCTs, the arm including HC users with AMH data before and during/after HC was used as a cohort study 
for the purpose of this review.  
Articles were divided into two main study designs including eight cohort/RCT studies comparing circulating 
AMH before and during HC (Table 2) and seven cross-sectional studies comparing AMH data between HC 
users versus non-users (Table 3).  
Types of hormonal contraception 
Three studies did not specify the HC (Tables 3).18,20,22 All remaining 12 studies used combined HC (CHC) either 
as the only HC (10 studies)16,19,21,23-26,29,36-38 or in addition to POC (two studies).23,27 HC components for each 





Duration of hormonal contraception use 
The review included three short-term (2-3 weeks),16,26,36 three medium-term (2-6 months),21,25,27 four long-term 
(>1 year)19,22,24,29 and three varied/unspecified-term18,20,23 studies. Three studies evaluated AMH after HC 
discontinuation in long-term users.22,37,38 
Participants 
Majority of studies used appropriate inclusion and exclusion criteria. All short- and medium-term studies 
defined their participants as normo-ovulatory,16,21,25-28 with one study including a second group of PCOS users25 
(excluded from the review) (Table 2). While most long- and varied-term studies included healthy women with 
no information on menstrual status before starting HC (Table 3). With regards to age, all studies included 
women in their twenties or thirties (Tables 2 and 3). 
AMH assays  
Seven studies measured serum AMH concentrations using DSL enzyme-linked immunosorbent sensitive assay 
(ELISA) (DSL-10-14400, Diagnostic Systems Laboratories, Inc., Webster, USA).16,18,20,25,29,36,38 The reported 
limits for detection varied between 0.006 and 0.1 ng/mL, and the intra- and interassay coefficients of variation 
(CV) were 5.0 and 8.0%, respectively. 
Four studies assayed serum AMH levels using the IOT AMH ELISA kit (Immunotech-Beckman, Marseilles, 
France).19,24,26,27 The sensitivity of the assay is 0.7 pmol/l, and the intra- and inter-assay coefficients of variation 
were 12.3% and 14.2%, respectively. 
Three studies analysed serum AMH concentrations using AMH Gen II ELISA (Diagnostic System 
Laboratories-Beckman Coulter Inc) with a detection limit of 0.08 ng/mL.21-23 The interassay and intra-assay 
coefficients of variation were 3.35% and 4.0%, respectively. 
One recent study measured serum AMH using the fully automated Access AMH assay (Beckman Coulter, Brea, 






Circulating AMH and other ovarian reserve markers in CHC users 
Short-term CHC users (2-3 weeks) 
Three studies (n=243) assessed circulating AMH in healthy short-term CHC users (Table 1).16,26,36 Two of these 
studies (n=223) reported no change in circulating AMH after 2-3 weeks of CHC starting in the early follicular 
phase.26,36 The third study (n=20) reported a decline in AMH after 2-3 weeks of COCP starting in mid-luteal 
phase.16 The discrepancy between these results could be attributed to different timing of starting the COCP.  
Only one small study conducted by Streuli and colleagues scored high on the quality assessment tool.26 This was 
one of the earlier studies assessing circulating AMH (using IOT) in 14 norm-ovulatory women before and after 
three weeks (cycle days 5-25) of CHC (oral pills, n=7; vaginal ring, n=7). Although this was an RCT, each arm 
was suitable for this review as a cohort study with AMH data before and after CHC. The results showed no 
change in circulating AMH with either CHC forms. However, the authors stated that further studies were still 
needed to verify their findings.  
Andersen et al. measured circulating AMH (using DSL), AFC and OV before and after 2-3 weeks of combined 
oral contraceptive pill (COCP) starting on cycle day 2-3 in 209 normo-ovulatory women scheduled for in-vitro 
fertilization (IVF).36 Measurements were performed on day 2-3 before and five days after the last COCP (before 
starting IVF). Although this was a multicentre RCT comparing IVF outcomes in women receiving COCP versus 
women receiving no HC, we included the COCP arm as a cohort study where AMH data were reported before 
and after COCP. The results showed no change in circulating AMH (median [5th, 95th percentiles] 2.2 [0.5, 6.3] 
versus 2.1 [0.6, 4.6] ng/ml), AFC or OV.  
Arbo et al. assessed circulating AMH (using DSL), AFC (2-10mm) and OV in 20 normo-ovulatory women 
before and after 2-3 weeks of COCP starting in midluteal phase (Table 2).16 Ovarian reserve was assessed on 
cycle day 3 before and after COCP (or 14 days after COCP in the absence bleeding). Circulating AMH 
significantly (p=0.04) decreased from median [IQR] 3.02ng/mL [1.2, 6.4] to 2.2ng/mL [0.9, 3.1] after COCP. 





reduction was due to reduced production by the arrested follicles. The weakness of this study is its small size 
and the unusual timing of the HC.  
Medium-term CHC users (2–6 months) 
Three studies assessed circulating AMH after 2-6 months of CHC in 103 women (Table 2).21,25,27 All three 
studies scored ≥6 on the quality assessment scale. Two studies (n=61) using cyclical CHC revealed no change of 
circulating AMH25,27 and one (n=42) using continuous COCP reported a decline in circulating AMH.21  
Somunkiran et al. assessed circulating AMH (using DSL), OV, AFC (2-9 mm), FSH and E2 before and after six 
months of cyclical COCP in 15 normo-ovulatory women.25 They reported no change in AMH (1.93±0.51 versus 
2.11±0.56 ng/ml). However, OV, follicle number and size, FSH and E2 significantly decreased at six-months. 
The authors explained the lack of any change in AMH despite the decrease in small antral follicles by the 
continued production of AMH from smaller undetectable follicles. The final conclusion was that AMH may be 
considered as the only valid ovarian function marker in COCP users. However, given the small size of the study 
and the lack of sample size calculation, these results should be considered preliminary.   
Li et al. measured circulating AMH (using Gen II) in 46 women before and after 3-4 months of cyclical CHC 
(COCP, n=23; injectable, n=23).27 They reported no change in circulating AMH in either of the groups. Pre-
treatment median (IQR) circulating AMH were 27.2 (26-35) pmol/l for COCP and 20.9 (13.2-35.4) pmol/l for 
injectable CHC users. Post-treatment values were 17.1 (8.5-28.6) and 26.9 (9.0-44.0) for COCP and injectable 
CHC respectively. Although the study was powered (90%) to detect a difference of 1 SD of AMH, the authors 
did not clarify what that SD was. It seems that this SD was large and the study was not powered to detect 
smaller but clinically important differences. This is supported by the obvious trend towards a large drop of 
circulating AMH in COCP users from 27.2 to 17.1 pmol/L. The lack of statistical significance here could purely 
be due to the small sample size. Other limitations of this study include the variation of timing of AMH 
measurement and the lack of any information on the menstrual status of the participants and whether they 





Kallio et al. assessed circulating AMH (using Gen II assay) in normo-ovulatory women (n=42) before and after 
five and nine weeks of continuous CHC including COCP (n=13), transdermal patches (n=15) and vaginal rings 
(n=14).21 They reported a significant (P<.001) decline in circulating AMH with all CHC forms after nine weeks 
(COCP, 3.9±3.0 vs. 1.9±1.5 ng/Ml; transdermal, 3.9±3.6 vs. 2.0±1.3 ng/mL; vaginal ring, 4.3±3.5 vs. 2.3±1.2 
ng/mL). Similar significant (P<.001) declines were observed in circulating FSH, inhibin B and E2 in all groups 
at five and nine weeks of treatment. The authors hypothesised that the decline of circulating AMH could be due 
to reduced follicular granulosa cell mass as a result of the CHC-induced FSH suppression. However, it is known 
that the earlier follicular growth is independent of FSH.39 The main limitation of this study, is its small size and 
the lack of power calculation. 
Long-term CHC users (>1 year) 
Four cross-sectional studies investigated ovarian reserve in long-term users (n=1414) of CHC versus non-users 
(n=2273) (Table 3).19,22,24,29 Three studies reported lower circulating AMH in CHC users (n=1380) compared to 
non-users (n=2237).19,22,24 The remaining study showed no difference in circulating AMH in CHC users (n=34) 
versus non-users (n=36).29 
With regards to AFC, two studies showed reduction in the number of larger follicles, but no change in the 
number of smaller follicles measuring 2-4mm (22) or 2-6mm.29 The third study reported lower AFC of all 
follicle size categories in CHC users.19 
Only one study in this group rated high on the quality assessment scale.29 This was a well-designed cross-
sectional study assessing circulating AMH (using DSL assay), AFC and OV in 34 healthy women using COCP 
for >1year (average (range) 3.16 (2.4-6.0) Years) and 36 age-matched healthy non-HC users. Assessment was 
carried out in the early follicular phase in both groups. They found no differences in circulating AMH or the 
number of the 2-6mm follicles between the two groups. While, follicles measuring >6mm and OV were 
significantly (P< 0.001) lower in COCP users versus non-users. Circulating FSH, LH and E2 were significantly 
(P<0.05) lower in the COCP group. They concluded that prolonged use of COCP suppresses pituitary 





number of small antral follicles. The main limitation of this study was the lack of power calculation for AMH as 
the sample size was calculated for AFC as the primary outcome. 
Bentzen et al. compared early follicular (day 2-5 or pill free interval) circulating AMH (using IOT assay), AFC 
and OV among 228 CHC users (COCP, n=217; vaginal rings, n=11) versus 504 non-users.19 COCP included 
monophasic with 20μg EE (n=101), monophasic with 30-35μg EE (n=96) and bi-/triphasic preparations (n=20). 
After adjusting for age, they reported 30% (95%CI, 19.9-38.5%) lower AMH, 30% (95%CI, 23.6-36.7%) lower 
AFC (all follicle sizes) and 42% (95%CI, 37.8-46.3%) lower OV in CHC users versus non-users.  They also 
found a trend of negative linear association between duration of CHC and ovarian reserve parameters. They 
calculated a decline of 2.3% in AMH (not statistically significant), 2.5% of AFC (P=0.02) and 2.7% of OV 
(p=0.005) for every year of CHC. No dose-response relation was found between the dose of EE and AMH or 
AFC. They concluded that circulating AMH and AFC are lowered in a duration-, but not dose-dependent 
fashion in COCP users and that these makers may not be reliable in assessing ovarian reserve in these women. 
In a large population-based cross-sectional study, Dolleman et al. investigated the effect of various reproductive 
and lifestyle factors including oral HC on circulating AMH (using Gen II assay).22 The HC type was not 
specified and its duration varied widely (>1 to >20 years). They calculated age-specific AMH percentiles using 
general linear modelling with CG-LMS (Cole and Green, Lambda, Mu, and Sigma model). They reported that 
current oral HC users (n=908) had an age-specific AMH of 11 percentiles lower (P<.0001) than non-users 
(n=1090). They found no significant effect of HC duration on AMH in women not exceeding 20 years of use. 
Women who used HC >20 years had an 8.8±4.2 percentiles lower age-specific AMH compared to women who 
used HC for ≤1 year.  
In a large cross-sectional study including 887 women aged 19-46 attending for fertility assessment, Petersen et 
al. compared circulating AMH (using IOT assay), AFC and OV in long-term CHC users (n=244) versus non-
users (n=643).24 CHC included COCP (n=225) and vaginal rings (n=19). The median HC duration was 12 years 
(90% population limit; 4.0, 18.4 years). After adjusting for age by linear regression analysis, they found a 19% 





CI 45.1-53.7%) in CHC users versus non-users. Notably, the decline in AFC was only observed in the 5-10mm 
follicles, but the 2-4mm follicles increased in CHC users. HC users and non-users were comparable regarding 
age, BMI, smoking and maternal age at menopause. They concluded that CHC seem to have a major negative 
impact on the OV, and a moderate impact on AFC and AMH. One weakness in this study is the inclusion of 
self-referred women attending the Fertility Assessment Clinic, which may not reflect the general population. 
Further, the timing of AMH assessment varied in different women, which could be a confounding factor.  
CHC users for varied/unspecified duration 
Three cross-sectional studies investigated ovarian reserve in HC users (n=202) versus non-users (n=312), but 
did not specify the duration of HC.18,20,23 All studies reported lower circulating AMH in HC users compared to 
non-users (Table 2). The three studies were considered of low quality with a low score on the modified 
Newcastle-Ottawa tool. 
In a small cross-sectional study Shaw et al. reported significantly (P<0.001) lower median AMH (using DSL) 
level (3.0 pmol/L (95% CI, 2.1-3.8 pmol/L) in users of oral HC (n=14) compared to that (4.6 (95% CI, 3.9-5.2) 
pmol/L) of non-users (n=121).18 The results were adjusted for age and all women were aged 33-45 years. 
Unfortunately, neither the type nor the duration of HC was specified in this study. Furthermore, timing of AMH 
measurement in the cycle was not mentioned. 
In a population-based cross-sectional study, Kristensen et al. assessed circulating AMH (using DSL) in 180 HC 
users versus 76 non-users.20 HC included COCP (n=161), combined vaginal rings (n=12), progestogen only 
contraceptives (POC, n=7). Unfortunately, the duration of HC was not specified in this study and AMH 
measurement was taken at varied times of the menstrual cycle. Although the focus of this study was mainly to 
study the association between circulating AMH and AFC, androgens, and menstrual cycle characteristics in HC 
users versus non-users, AMH data in HC-users versus non-users were also presented and were considered 
relevant to this review. Circulating AMH in HC users (Median (IQR) 2.5 (1.5–3.5) ng/mL were significantly 
(P=0.01) lower than that (2.9 (1.8–4.3) ng/mL) in non-users. The study also found a strong positive association 





strong relationship between AMH and AFC was observed in both users and nonusers. Analysis after exclusion 
of the seven POC users did not change the above results. 
Johnson et al. compared circulating AMH (using Gen II) and AFC in HC-users (n=50) including cancer 
survivors (n=42) and healthy controls (n=8) versus non-users (n=189) including cancer survivors (n=84) and 
healthy controls (n=115).23 For the purpose of this review and to avoid confounding effect of chemotherapy on 
ovarian reserve, we included only the healthy HC users (n=8) and non-users (n=115). After adjusting for 
confounders, AMH was 55% lower among HC users (geometric mean (95% CI) 1.02 (0.67-1.56) ng/ml, 
p<0.001) versus non-users (2.31 (2.02–2.63) ng/ml). AFC was 20% lower among healthy CHC users versus 
non-users (RR 0.80, 95% CI 0.69-0.93). HC was COCP in most users, but exact numbers were not presented. 
AMH and AFC were assessed in the early follicular phase in the majority of cases. Although this study was 
described as a longitudinal cohort study, data used in this review were taken at one point and it is therefore 
considered a cross-sectional design. The weakness of this study is its small size. Furthermore, HC users were 
defined as women who used HC within the preceding three months of ovarian reserve assessment, meaning that 
some HC users were non-users at the time of assessment.  
AMH after CHC discontinuation in long-term users 
Three studies evaluated ovarian reserve after discontinuation of HC in long-term users (n=1324), of which two 
were cross-sectional studies assessing AMH in previous users versus women who had never used HC (Table 
3).22,37 The third study was a cohort study comparing AMH during and after HC discontinuation.38 All studies 
suggested that the reduction of circulating AMH observed in long-term HC users seem to be reversable after 
discontinuation.  
Two studies scored ≥ 6 on the quality assessment tool,37,38 while the remaining study scored low.22  
Kucera et al. compared circulating AMH (using Access AMH assay (Beckman Coulter, Brea, CA) in 105 
previous long-term COCP users (one year after discontinuation) versus 44 women who had never used HC.37 





between previous HC users (median (IQR), 2.89 (1.57, 4.46) ng/ml) and women who had never used HC (3.37 
(2.07, 4.42) ng/ml). They concluded that there was no negative impact of previous HC use on circulating AMH.  
In their large cross-sectional study, Dolleman et al. compared circulating AMH (measured with Gen II assay) in 
previous HC users (n=1194) versus healthy controls who had never used HC. They reported that that previous 
HC use was not associated with low AMH values.22  
Van den Berg et al. measured circulating AMH (using DSL assay), AFC and OV during CHC (on day 7 of the 
hormone-free interval (D7-HFI)) and in two subsequent natural cycles after CHC discontinuation in 25 users 
(median (IQR) duration, 20(57) months).38 CHC included COCP (n=23, mono-/triphasic 20-50µg oestrogen 
preparations), patch (n=1) and vaginal ring (n=1). They reported that D7-HFI AMH (mean±sd, 2.0±1.2 ng/ml) 
remained unchanged in natural cycle-1 (2.0±1.3ng/ml), but significantly (p<0.001) increased to 2.6±1.3ng/ml in 
the natural cycle-2. AFC and OV increased after HC discontinuation from the D7-HFI to natural cycle-1 and 
from natural cycle-1 to cycle-2. The authors also reported that FSH, AMH and AFC values measured on D7-
HFI could be used to predict values of natural cycle-2 after HC discontinuation using calculated equations, 
which require validation.38 
Circulating AMH in users of progestogen only contraception 
Only two studies investigated circulating AMH in a small number of users of progestogen only contraception 
(POC).23,27 Of these only the study by Li et al. provided AMH data separately for 49 POC users including POP 
(n=9), POI (n=20) and Mirena (n=20).27 The results showed that pre-treatment serum AMH levels remained 
unchanged after 3-4 months of POC. The remaining study did not provide separate analysis for the POC users.23 
Discussion  
To the best of our knowledge, this is the first systematic review to investigate the status of circulating AMH and 
other ovarian reserve markers in a large number of HC users (n=3440). We have found two main types of study 
designs addressing this issue. The first type included short- (2-3 weeks) and medium- (2-6 months) term cohort 





varied-term cross-sectional studies comparing HC users versus non-users. The limited data from short- and 
medium-term studies involving healthy non-PCOS women showed no change in circulating AMH during 
cyclical CHC. On the other hand, AMH was reduced after nine weeks of continuous CHC.21  
Apart from one publication,29 all long-term studies as well as studies with unspecified/varied HC duration have 
consistently showed a markedly lower circulating AMH, AFC and OV in HC users versus non-users. The 
magnitude of AMH decline in long-term HC users varied widely from 14 to 55%. Three long-term studies 
provided evidence for AMH recovery after discontinuation of HC. Only one relatively small, but well-designed 
study by Deb et al. showed no change of AMH in 34 CHC users.29 The discrepancy between this study and the 
other long-term studies could be attributed to differences in the study population and/or methodology. Whilst 
Deb and colleagues27 measured serum AMH in the early follicular phase, Petersen and colleagues24 measured it 
at a random time of the cycle and Panidis and colleagues28 measured it in mid-follicular phase (day 5-7). 
Furthermore, Deb et al. compared the median (range) AMH in users versus non-users,29 while several studies 
estimated the percentage difference in AMH or the AMH percentiles. Moreover, the age of women in the study 
by Deb et al. was much younger (25.4±4.2 years) compared to most other studies.29  
 With regards to AFC and OV, two short-term studies showed no change in AFC,16,36 but one study showed a 
reduction in the follicle size and OV.16 Two medium-term studies showed a decrease in OV and AFC in PCOS 
(15, 23) and non-PCOS users of CHC.25 Several long-term studies consistently reported a decline in AFC 
affecting either all follicle sizes19,23 or only large follicles.24,29 Several studies have reported reduction in OV. 
Two studies reported recovery of AFC and OV after HC discontinuation.37,38  
Data on the effect of HC duration on AMH in long-term users are limited and conflicting. One study found a 
negative linear association between duration of CHC and ovarian reserve parameters,19 while another larger 
study reported no effect of HC duration on the magnitude of AMH decline, except in women exceeding 20 years 
of HC use.22 
The majority of studies used COCP with very few using either other combined forms such as patches, vaginal 





doses or different progestogen components. Also, only limited data are available on the effect of progestogen 
only preparations showing no effect on circulating AMH.   
The wide variation in the magnitude of AMH decline (14-55%) in long-term studies could be attributed to the 
variations in duration and types of HC, populations investigated and the methodologies applied.  
The observed decline in circulating FSH and E2 in most studies was expected and could be explained by HPO-
axis suppression via a negative feedback mechanism. However, the decline of circulating AMH in long-term 
HC users is somewhat surprising as it has long been believed that AMH is an autocrine/paracrine factor, which 
is not influenced by the HPO-axis.8-12 However, as mentioned in the introduction, more recent studies revealed 
that circulating AMH fluctuates considerably during the menstrual cycle and may therefore be influenced by the 
HPO-axis.13,14 It is therefore possible that the decline in AMH in long-term HC users is due to HPO-axis 
suppression.   
Based on the findings of this review, circulating AMH seems to be markedly supressed in long-term CHC users 
and cannot therefore be used for the accurate assessment of ovarian reserve in these women. Furthermore, AMH 
levels in long-term users cannot be used to calculate or predict the normal values due to the uncertainty about 
the magnitude of its decline. We therefore recommend that if assessment of ovarian reserve is required in 
chronic HC users, the HC should be discontinued for a washout period before measuring AMH and other 
markers. The length of this washout period requires further research to estimate the time required for the full 
recovery of circulating AMH. 
Apart from one study, which used the fully automated Access AMH assay,38 all studies included in this review 
used either the DSL, IOT or GEN II ELISA AMH assay kits. It is now well established that these kits, which are 
no longer in use, gave varied results and had different sensitivities and inter- and inter-assay coefficients of 
variation. The IOT assay (Immunotech, Beckman Coulter, Marseille, France) has been found to produce AMH 
concentrations 40% higher compared with the DSL assay (Diagnostic Systems Laboratories), making it difficult 
to combine/compare results from different Studies.40 Gen II assay, which was first introduced by the merging of 





the IOT assay (41-43). The Gen II assay suffered significant interference problems until July 2013 and was later 
modified to overcome this issue.44 Furthermore, inter-laboratory variations and sample instability further 
complicate the interpretation and clinical implications of AMH values.44 Moreover, studies using AMH kits that 
produced low values (e.g. DSL) may not be able to detect differences in AMH levels especially in pobulations 
with low AMH levels.  
Although this systematic review has consistently shown marked decline in circulating AMH in long-term HC 
users, these data should be interpreted with caution in view of the significant variations and high heterogeneity 
between the reviewed studies. Further well designed and sufficiently powered cohort studies are required to 
assess the short (<3months), medium (<1year) and long-term (>1year) status of circulating AMH during HC 
compared with pre-treatment baseline levels. This will be the appropriate design as it allows assessment of any 
changes in AMH in the same participant rather than comparing between users versus non-users, where several 
confounders could compromise the validity of the results. Based on this review, we suggest that any planned 
study should be powered to detect a 19-29% decline in serum AMH concentration after >1 year of HC. In 
addition to a robust design, future studies should use the most sensitive and widely used automated AMH 
assays. Furthermore, future studies should focus on one form of HC in each study.    
In conclusion, circulating AMH, AFC and ovarian volume seem to decline markedly in long-term HC users. 
Short- and medium-term cyclical CHC does not seem to affect AMH in normo-ovulatory women. However, all 
these data should be considered preliminary given the poor quality and/or the small size of almost all the 
studies. The effect of HC on AMH in PCOS women remains uncertain. We recommend that further well-
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Figure 1. Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) flow chart 























366 Records identified 
through database 
searching 
19 Full articles 
assessed for eligibility 
4 studies excluded: 
 1 lack of comparative AMH data 
 1 was a duplication 
 2 including PCOS women 
15 Studies included in 
systematic review 
347 Studies excluded as 
deemed not relevant 
366 Records screened 














































Table 1. Modified Newcastle Ottawa scale for risk of bias and quality assessment of the included studies 







Short-term studies      
Arbo et al. (14) 2007 * **** - 5 
Streuli et al. (24) 2008 * **** * 6 
Andersen et al. (34) 2011 ** *** - 5 
Medium-term studies      
Somunkiran et al. (25) 2007 - **** ** 6 
Li et al. (27) 2011 ** **** ** 8 
Kallio et al. (21) 2013 ** **** * 7 
Long-term studies      
Deb et al. (29) 2012 * *** ** 6 
Bentzen et al. (19) 2012 ** *** - 5 
Dolleman et al. (22) 2013 ** - - 2 
Petersen et al. (24) 2015 ** *** - 5 
Varied-term studies      
Shaw et al. (18) 2011 * - * 2 
Kristensen et al. (20) 2012 * *** - 4 
Johnson et al. (23) 2014 * * ** 4 
Previous HC users      
Kucera et al. (37) 2016 ** **** ** 8 








Table 2 characteristics of eight short- and medium-term studies comparing AMH before and during CHC  
 




Outcomes Pattern Duration Route n Outcome Kit 
Short-term studies (3 weeks)   
Arbo et al, 2007 (16) Brazil Cohort 20 Mid-luteal 3 weeks Oral1 20 29.1±4.1  DSL FSH, AFC, E2 





24.1±3.5 No change IOT FSH, AFC 
Andersen et al, 2011 (36) USA** RCT 209 Cyclical 3 weeks Oral1 209 31.8±3.7 No change DSL AFC, FSH, E2 
Medium-term studies (2 – 6 months)  
Somunkiran et al, 2007 (25) Turkey Cohort 15 Cyclical 6 months Oral2  25.1±6.9 No change DSL FSH, AFC, OV 





30 [26, 35] 
32 [26, 35] 
No change IOT – 










 Gen II FSH, E2 
 
* Age presented as mean±SD; median [interquartile]; mean(±SEM) 
** Multicentre trial in different countries: USA, Denmark, Germany, Spain, Turkey 
 
1 EE + desogestrel,  
2 EE + cyproterone acetate,  
3 ethinylestradiol + levonorgestrel,  
4 ethinylestradiol + drospirenone    
5 EE + etonogestrel 
6 Estradiol cypionate + Medroxyprogesterone acetate 
7 EE + norelgestromin 
 
Abbreviation: CHC, combined hormonal contraception; RCT, randomised controlled trial; OV, ovarian volume; IOT,   Immunotech AMH enzyme immunoassay; DSL, Diagnostic System 






Table 3 Characteristics of eight Cross-sectional studies comparing AMH between Long- (>1 year) and varied-term users versus non-users of HC  
 
Author Country 
n Contraception Age (years)* AMH 
Secondary 





Type  Route n Users  Non-users Outcome Kit 
Studies assessing AMH in current long-term HC users versus non-users 
Deb et al, 2012 (29) UK 34 36 
3.2*** 
(2.4-6.0) 
CHC Oral3 34 25.4±4.2 27.2±4.6 No difference DSL 
FSH, AFC, 
OV 









 (30%) IOT AFC 
Dolleman et al, 2013 (22) Netherlands 927 1418 > 1 NS Oral9 927 37.3±9.2   (11 percentile) Gen II – 








31.5±4.3 34.1±4.3  (19%) IOT AFC, OV 
Studies assessing AMH in current varied-term HC users versus non-users 
Shaw et al, 2011 (18) USA 14 121 NS NS Oral9 14 41± 2.48  (35%) DSL – 
Kristensen et al, 2012 
(20) 











 (14%) DSL FSH, AFC, E2 










 (55%) Gen II AFC 
Studies assessing AMH in previous long-term HC users versus non-users 
Dolleman et al, 2013 (22) Netherlands 1194 1418 NS NS Oral9 1194 37.3±9.2 No difference Gen II – 






CHC Oral9 105 32.1 (27- 34) 31.2 (2 3-34) No difference Access  – 
 
* Age presented as mean±SD, median [interquartile], mean (range), 
** median (90% population limit) 
***average (range) 
mean (range) 
Age of all women in both groups (study and control) 
 intra-uterine device, 1; injection, 1 
 
3 ethinylestradiol + levonorgestrel,  
8 EE + unspecified progestogen 






Abbreviation: HC, hormonal contraception; CHC, combined hormonal contraception; NS, Not-specified; POC, progesterone only contraceptive;  OV, ovarian volume; EE, ethinyl oestradiol; 
IOT,   Immunotech AMH enzyme immunoassay; DSL, Diagnostic System Laboratories ELISA AMH kit; Gen II, Generation 2 ELISA AMH kit; Access, Chemiluminescent kit Access AMH 
(Beckman Coulter, Brea, CA); FSH, follicle stimulating hormone; AFC, antral follicle count; E2, oestradiol;  
 
 
 
 
 
 
 
 
